From MarketBeat:

Pharming Group saw a significant growth in short interest in December, with a total of 1,000 shares, an increase of 100.0% from December 15th. The short-interest ratio is currently 0.4 days based on an average daily volume of 2,500 shares.

A recent Form 13F filing reveals that Orion Portfolio Solutions LLC has bought 11,715 shares of Pharming Group in the third quarter. Institutional investors and hedge funds now hold 0.04% of the company’s stock.

Shares of NASDAQ: PHAR traded at $12.90, down $0.10 on Friday. With a market capitalization of $863.53 million and a PE ratio of -40.35, Pharming Group has a 12 month low of $9.65 and a high of $17.81.

Pharming Group’s earnings data indicates an EPS of $0.05 for the quarter, with a revenue of $66.66 million. The company had a negative return on equity of 10.25% and a negative net margin of 10.08%. Analysts predict that it will post -0.03 EPS for the current fiscal year.

Pharming Group N.V. develops and commercializes protein replacement therapies for the treatment of rare diseases. Its commercialized product, RUCONEST, is a plasma-free rhC1INH protein replacement therapy for treating acute hereditary angioedema attacks.



Read more: Short Interest in Pharming Group (NASDAQ:PHAR) Expands By 100.0%